Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
- Meyer, Jonathan M.
- Davis, Vicki G.
- Goff, Donald C.
- McEvoy, Joseph P.
- Nasrallah, Henry A.
- Davis, Sonia M.
- Rosenheck, Robert A.
- Daumit, Gail L.
- Hsiao, John
- Swartz, Marvin S.
- Stroup, T. Scott
- Lieberman, Jeffrey A.
Publication date
January 2008
DOIAbstract
The metabolic syndrome (MS) is associated with increased risk for diabetes mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial
Add to ORKG